Abstract
Background and Aims: A panel of experts (the Poseidon Group) introduced a new and more detailed stratification for poor ovarian responders in order to predict the prognosis of IVF outcome according to the sensitivity to FSH. However, various arguments about the management strategy of these patients still remain, including the convenience and the cost. Therefore, this study was conducted to compare the efficacy of mild and conventional GnRH antagonist ovarian stimulation prescribed in patients classified in Poseidon Group 4.Methods: This retrospective cohort study included 359 poor responder patients (Poseidon Group 4) treated with mild or conventional GnRH antagonist stimulation regimens from 8/2017 to 7/2019 at Tam Anh Hospital ART Center. The main outcomes were the index of Follicular Output Rate (FORT) or Follicle to Oocyte Index (FOI), the number of day-2 embryos and top-quality embryos obtained. The t-test and Mann–Whitney U test in SPSS v25.0 was used to analyze the continuous data and Chi-squared/Exact test was used for binary variables. Multiple linear regression analysis was done by using Stata versions 15.0 to measure association between primary endpoints with stimulation regimen controlled for covariates and possible confounding factors.Results: In the overall group of poor responders, the conventional GnRH antagonist protocol performed better than the mild protocol. Subsequently, data were analyzed according to the AFC. In women with AFC < 3, no significant differences were observed between the 2 regimens regarding FORT (p = 0.71), FOI (p = 0.12), the number of day-2-embryos (p = 0.052) and the number of top-quality embryos (p = 0.26). In contrast, in women with AFC ≥ 3, mild stimulation regimen resulted in significantly poorer outcome compared to the conventional GnRH antagonist regimen, regarding FORT (p < 0.01), FOI (p < 0.01), the number of day-2-embryos (p < 0.01) and top-quality embryos (p = 0.01).Conclusions: Considering poor responders classified in Poseidon Group 4, both ovarian stimulation regimens resulted in similar outcome for patients with a very low ovarian reserve (AFC < 3). In contrast, the GnRH conventional antagonist protocol with maximum initial FSH dose (300–375 IU/day) and supplementary LH (75–150 IU/day) was more effective than the mild one for patients whose ovarian reserve was less reduced. The Clinical Trial was approved by the Ethnical Biomedical Research Committee Tam Anh General Hospital.
Highlights
Background and AimsA panel of experts introduced a new and more detailed stratification for poor ovarian responders in order to predict the prognosis of IVF outcome according to the sensitivity to FSH
To overcome those limitations of Bologna criteria, a group of scientists/clinicians published in 2016 a new classification called Poseidon (Patient–Oriented Strategies Encompassing IndividualizeD Oocyte Number) aiming at defining some subgroups with different prognosis according to their ability to get at least one euploid blastocyst for transfer [11]
It has been suggested to assess the actual response to FSH by measuring Follicular Output Rate (FORT) and Follicle to Oocyte Index (FOI) which both reflect the follicular sensitivity to FSH [18, 19]
Summary
Background and AimsA panel of experts (the Poseidon Group) introduced a new and more detailed stratification for poor ovarian responders in order to predict the prognosis of IVF outcome according to the sensitivity to FSH. An increasing number of women facing a decreased ovarian reserve are asking for assisted reproductive technology to get a child [2] This subgroup represents about 37% of the overall IVF population [3], even if prognosis is very poor with a live birth rate between 6.7 and 11.4% [4,5,6,7,8]. As 2 out of 3 criteria could be used to define a POR, several types of patients with different prognosis factors could be integrated within this category To overcome those limitations of Bologna criteria, a group of scientists/clinicians published in 2016 a new classification called Poseidon (Patient–Oriented Strategies Encompassing IndividualizeD Oocyte Number) aiming at defining some subgroups with different prognosis according to their ability to get at least one euploid blastocyst for transfer [11]. FOI improvement should increase the chance of having euploid embryos and the success rate [19]
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.